Physician profile
Clevius A Curry
NPI 1487989927
$2,813.60
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $524 · 2020: $991 · 2021: $1,131 · 2022: $145 · 2023: $23.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $409.28 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $245.76 | 2019-2021 | |
| Amgen INC. | $235.58 | 2020-2021 | |
| Genentech USA, INC. | $221.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $156.20 | 2019-2021 | |
| Seagen INC. | $112.55 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.84 | 2019-2022 | |
| Lilly USA, LLC | $79.05 | 2019-2021 | |
| Abbvie INC. | $77.35 | 2020-2023 | Venclexta |
| Eisai INC. | $70.50 | 2019-2021 | |
| Incyte Corporation | $69.92 | 2020-2021 | |
| Kite Pharma, INC. | $64.15 | 2020-2021 | |
| Emd Serono, INC. | $64.12 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.41 | 2020-2021 | |
| Astellas Pharma US INC | $61.41 | 2020-2021 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clevius Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.